This document is a page from a December 12, 2011 issue of The New Yorker, stamped with 'HOUSE_OVERSIGHT_029929', indicating it is part of a Congressional investigation. The text is an article discussing the medical efficacy and scientific definition of the 'placebo effect,' featuring interviews with Robert Temple of the FDA and referencing studies by Danish researchers. While the content is scientific, its inclusion in the oversight file suggests it may be relevant to inquiries regarding medical funding, research practices, or specific individuals (like Epstein) who may have had interests in these scientific fields.
The document is JSON code describing an article about the pharmaceutical company Celgene. The article alleges that Celgene used a federal safety program (REMS) to block generic competition for its drugs, Revlimid and Thalomid, leading to lawsuits from companies like Mylan. The text also mentions a patient paying high costs and a professor criticizing Celgene's actions.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity